BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3750371)

  • 1. Hemodialysis clearance of chloroquine in uremic patients.
    Akintonwa A; Odutola TA; Edeki T; Mabadeje AF
    Ther Drug Monit; 1986; 8(3):285-7. PubMed ID: 3750371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodialysis of acetaminophen in uremic patients.
    Marbury TC; Wang LH; Lee CS
    Int J Artif Organs; 1980 Sep; 3(5):263-6. PubMed ID: 7461859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dyphylline elimination by uremic patients.
    Lee CC; Wang LH; Majeske BL; Marbury TC
    J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.
    Wang LH; Lee CS; Majeske BL; Marbury TC
    Clin Pharmacol Ther; 1981 Mar; 29(3):365-72. PubMed ID: 7471607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.
    Lee CS; Marbury TC; Benet LZ
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):69-81. PubMed ID: 7381692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between effective ionic dialysance and in vivo urea clearance during hemodialysis.
    Lindsay RM; Bene B; Goux N; Heidenheim AP; Landgren C; Sternby J
    Am J Kidney Dis; 2001 Sep; 38(3):565-74. PubMed ID: 11532690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.
    Zhang ZH; Mao JR; Chen H; Su W; Zhang Y; Zhang L; Chen DQ; Zhao YY; Vaziri ND
    Clin Biochem; 2017 Dec; 50(18):1078-1086. PubMed ID: 28928007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing residual renal function and efficiency of hemodialysis--an application for urographic contrast media.
    Sterner G; Frennby B; Månsson S; Ohlsson A; Prütz KG; Almén T
    Nephron; 2000 Aug; 85(4):324-33. PubMed ID: 10940743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
    Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
    Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodialysis of theophylline in uremic patients.
    Lee CS; Marbury TC; Perrin JH; Fuller TJ
    J Clin Pharmacol; 1979 Apr; 19(4):219-26. PubMed ID: 438357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of primidone elimination by uremic patients.
    Lee CS; Marbury TC; Perchalski RT; Wilder BJ
    J Clin Pharmacol; 1982 Jul; 22(7):301-8. PubMed ID: 7107978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodialysis clearance of total and unbound lidocaine.
    Jacobi J; McGory RW; McCoy H; Matzke GR
    Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodialysis of mefenamic acid in uremic patients.
    Wang LH; Lee CS; Marbury TC
    Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites.
    Antal EJ; Wright CE; Brown BL; Albert KS; Aman LC; Levin NW
    J Clin Pharmacol; 1986 Mar; 26(3):184-90. PubMed ID: 3958223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of end-stage renal disease and dialysis modalities on blood ammonia level.
    Vaziri ND; Khazaeli M; Nunes ACF; Harley KT; Said H; Alipour O; Lau WL; Pahl MV
    Hemodial Int; 2017 Jul; 21(3):343-347. PubMed ID: 27804262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionuclide method for evaluating the performance of hemodialysis in vivo.
    Bihl GR; Bird NJ; Peters C; Bradley JR; Peters AM
    Kidney Int; 2005 Feb; 67(2):721-31. PubMed ID: 15673322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo.
    Sombolos K; Tsitamidou Z; Kyriazis G; Karagianni A; Kantaropoulou M; Progia E
    Am J Nephrol; 1997; 17(5):406-12. PubMed ID: 9382156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.